NATA’s Executive Director to present keynote talk at the second annual Oligonucleotide Therapeutics and Delivery Conference
Professor Nick Lench, Executive Director of the Nucleic Acid Therapy Accelerator (NATA) is set to give a keynote talk at the second annual Conference on Oligonucleotide Therapeutics & Delivery, taking place on 21 and 22 September 2022 in London. Delegates will have the opportunity to hear an overview of NATA’s mission, aims and approach to supporting the development of RNA therapeutics.
Professor Lench will also join Peter Oliver, Head of Biology at NATA and Ritwick Sawakar, Investigator at the Medical Research Council (MRC) Toxicology Unit to run an associated workshop exploring ‘Encapsulation of Cargos for Effective Delivery’. Taking place on 20 September, the workshop will cover the pros and cons of different encapsulation approaches, methods to achieve preferential uptake, the cell biology of uptake, models for in vivo testing of encapsulation approaches, and safety concerns around encapsulation.
Building on the success of previous years of the RNA Portfolio, the second annual Oligonucleotide Therapeutics and Delivery Conference will bring together academic and industry experts from big pharma and leading biotechs to gain an expert and holistic view of the latest developments in the industry.
By attending the conference attendees will have the opportunity to:
- Meet with NATA’s senior leadership and discuss collaboration opportunities.
- Listen to case studies of pre-clinical and clinical research in areas such as oncology, as well as what can be learned for future clinical trials.
- Deepen their understanding of oligonucleotide therapeutic delivery and explore the latest innovations in extrahepatic oligonucleotide delivery and target specificity.
- Understand the regulatory and Chemistry, Manufacturing and Controls (CMC) environment surrounding oligonucleotide therapeutic development.
- Explore developments in oligonucleotide chemistries and novel applications of antisense oligonucleotides and siRNAs.
- Engage in the latest innovations in oligonucleotide therapeutics such as utilising AI machine learning to drive the discovery of novel therapeutics.
Interested parties can view the programme and speaker line-up and register for the conference and workshop at www.oligonucleotide.co.uk.